Somatostatin Receptor 1 Antibodies

The somatostatin receptor subtype 1 (SST1, SSTR1) is a class A G protein-coupled receptor (GPCR) that is activated by the endogenous peptides somatostatin-14 and somatostatin-28. SST1 primarily couples to Gi/o proteins, resulting in inhibition of adenylyl cyclase, reduced intracellular cAMP production, activation of G protein-gated inwardly rectifying potassium channels, and suppression of voltage-gated calcium channels. The receptor is widely expressed in the central nervous system, including the cerebral cortex, hippocampus, hypothalamus, and spinal cord, as well as in peripheral tissues such as the gastrointestinal tract, pancreas, immune cells, and selected endocrine and neuroendocrine tumors. SST1 modulates neurotransmitter release, neuronal excitability, nociception, gastrointestinal motility, and endocrine secretion, and has also been implicated in the regulation of cell proliferation and immune responses. Compared with SST2 and SST5, SST1 plays a more prominent role in neuromodulation than in the inhibition of hormone secretion. Several subtype-selective SST1 agonists have been developed for experimental use, including CH-275 and L-797,591, which have been valuable pharmacological tools for studying SST1 function in vitro and in vivo. However, no SST1-selective agonist has yet been approved for clinical use. Clinically available somatostatin analogs such as octreotide, lanreotide, and pasireotide exhibit only limited or negligible activity at SST1, with their therapeutic effects being mediated primarily through SST2 and, in the case of pasireotide, SST5.